terazosin has been researched along with alpha-synuclein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drazba, J; Gaivin, R; Gonzalez-Cabrera, P; McCune, DF; Papay, R; Perez, DM; Ross, SA; Yun, J; Zuscik, MJ | 1 |
| Choudhury, SR; Karmakar, S; Mohanbhai, SJ; Sardoiwala, MN | 1 |
2 other study(ies) available for terazosin and alpha-synuclein
| Article | Year |
|---|---|
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
Topics: Adrenergic alpha-Antagonists; alpha-Synuclein; Animals; Body Weight; Brain; Cerebellum; Disease Models, Animal; Female; Inclusion Bodies; Macromolecular Substances; Male; Mice; Mice, Transgenic; Motor Activity; Multiple System Atrophy; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Nitrates; Oligodendroglia; Phosphorylation; Prazosin; Receptors, Adrenergic, alpha-1; Spinal Cord; Survival Rate; Synucleins; Tyrosine; Ubiquitin | 2002 |
Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease.
Topics: alpha-Synuclein; Dopamine; Humans; Indoles; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Polymers; Prazosin; Serotonin; Synucleinopathies | 2022 |